We’re pleased to announce that in January 2019 a regular inspection of Good Manufacturing Practice was conducted by the State Institute for Drug Control in Prague. On the basis of their findings a GMP Certificate will be issued to the full extent of our authorization to manufacture medicinal products. The inspection report will also be provided to the US FDA under the MRA agreement (mutual recognition of GMP inspection results) between the US and EU. Quinta-Analytica is one of the first companies whose inspection report has been requested by the US FDA from the State Institute for Drug Control, and we’re honored to receive this recognition.”

Additional News

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona